ASI AbbVie New Horizons Research Award

 

ASI AbbVie New Horizons Research Award

Recognising an exceptional Australian or New Zealand Researcher who is leading in future-focused autoimmunity and inflammation research, with potential to advance scientific exploration in emerging areas.

Application round: 
Oct 22nd - Nov 1st 2021

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. Our heritage in Australia reaches back more than 80 years and we employ more than 450 people with our therapies currently benefiting more than 30,000 Australians. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments. Recently, we acquired Allergan which immediately diversified our business across several therapeutic areas: Immunology, Oncology, Virology, Neuroscience, Eye Care and Aesthetics.

For further information please visit www.abbvie.com.au. Follow @abbvie_AU on Twitter, FacebookInstagram or our LinkedIn page.

Background

AbbVie is committed to moving science forward to further develop medicines that can change the lives of people living with immune-mediated conditions such as Autoimmunity and Inflammation. 

Within these therapeutic areas, AbbVie has identified gaps in immunology research, particularly in the areas of new biological pathways, druggable targets and biomarkers, leading to paucity of innovation in therapeutics and precision medicine.  

To encourage investment in emerging areas, AbbVie will sponsor a research award that recognises an exceptional Australian or New Zealand Researcher who is leading in future-focused research that has potential to advance scientific exploration in emerging areas. 

In its inaugural year, ASI and AbbVie have partnered to launch the ASI AbbVie New Horizons Research Award,  initially focussing on Immunology.

Purpose

To support a mid career research Immunologist (10-20 years post-doctoral) with potential to advance research in emerging areas such as new biological pathways, druggable targets and biomarkers, within the fields of Autoimmunity, Inflammation, and other Immune-mediated Diseases (excluding Infectious Diseases).

The key objective of the ASI AbbVie New Horizons Research Award is to invigorate basic, translational or applied research in these areas of strategic importance. 

Eligibility

Mid-career researchers with 10-20 years post-doctoral research experience (counted at application deadline). Career disruptions (such as maternity leave) may be taken into account. Please provide details if you feel that you are eligible to apply.
Applicants are strongly encouraged to be Ordinary members of ASI at the time of application.

Application

  1. Click here to download the ASI AbbVie New Horizons Research Award application form.
  2. Include a C.V.
  3. Save your file as “LASTNAME YYYY_AbbVie” as a single pdf document
  4. Log in to your member profile and click on 'Applications'. 

If you do not have a member profile and wish to apply as an ASI Non-Member, please click here.

Assessment Criteria:

Award selection will be based primarily on C.V, track record, future potential, scientific merit and vision.

Preference will be given to individuals pursuing research within Autoimmunity and Inflammation research areas, that leverages big data to investigate the interplay between genomic networks, protein and other biomarkers and clinical phenotypes to discover new areas of biology for therapeutic targeting.

The Executive Committee reserves the right not to make an award.

Value

A single grant of AUD $80 000 for 1 year will be awarded to an individual via their research institute or affiliated university.

Terms and Conditions

  1. This is an award recognising the achievements and leadership potential of an exceptional Australian or New Zealand Researcher.  This funding is not considered to be a project-specific research grant, however funds are to be used to cover laboratory research expenditure.
  2. The Applicant is not obligated to provide a research proposal.
  3. The Applicant is not obligated to disclose ideas to AbbVie.
  4. There are no reach through rights to IP.
  5. The Applicant does not need to hold a current ASI membership however is strongly encouraged to join or renew ASI membership at the time of application.
  6. The Applicant must declare if he/she/they, has/have a professional services relationship with AbbVie.
  7. The Awardee may be asked to present to AbbVie discovery, R&D colleagues, or affiliate OneR&D colleagues.
  8. The Awardee will be required to attend the ASI scientific conference & Awards Ceremony to accept the award and to present briefly on their research interests.
  9. The Awardee must acknowledge AbbVie’s financial contributions to any research presented arising from use of AbbVie funds.
  10. The Awardee will be required to send AbbVie a letter on 12-month anniversary outlining how the funds were used to advance their research interests (non-confidential information only).
  11. The Awardee must ensure the funding is used for eligible research activities, which include salaries, consumables and research equipment, and include the breakdown of expediture in a summary table on the 12-month anniversary.
  12. The Awardee must sign an Attestation confirming compliance with AbbVie’s Use of Funds Requirements.
  13. The Awardee must submit a Newsletter contribution at the time of claiming the award and on the 12-month anniversary.
  14. The funds will be transferred to the Awardee’s institute / university / employer.

Successful Recipient - how to claim your ASI Award:

Please log in to your member profile to submit your Newsletter contribution, provide the signed Attestation as per #12 above, and to initiate the funds transfer process.  Funds will be transferred to the Awardee's Institute / university / employer.

The successful awardee will be formally presented their award at the Awards Ceremony at the end of the year.

 

© ASI 2021

ABN 76 330 189 856 | ARBN 084 971 559 | CAV A0016266B